FDA Inspection 1134615 — Laila Arash-Kaps, M.D.
The FDA completed an inspection of Laila Arash-Kaps, M.D. on November 6, 2020 in Mainz. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- November 6, 2020
- Fiscal Year
- 2021
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Mainz (Germany)
Additional Details
Clinical Investigator (CI)